Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy

NCT03113422 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT03113422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03113422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Completed
Start date
December 27, 2017
Completion date
January 6, 2023
Enrollment
56 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, non-hodgkin's lymphoma follicular, non-hodgkin's lymphoma, adult high grade